Internet Explorer does not cooperate well with this platform. Please see below for options that work with APNA eLearning Center programs.*

202-24: Keynote: Emerging Treatment Targets for Schizophrenia

Explore the state-of-the science regarding new treatments in the pipeline for schizophrenia with novel mechanisms of action that do not rely on dopamine receptor binding.

Presenter:  Jonathan M. Meyer, MD, DLFAPA

Disclosures:  The APNA planners and faculty, with the exception of those listed below, have no relevant financial relationships to disclose. All relevant financial relationships listed for these individuals have been mitigated. Off-label uses will be discussed during this presentation.

Jonathan M. Meyer, MD, is a speaker for Intra-Cellular Therapies Inc., AbbVie Pharmaceuticals, Alkermes, Axsome Therapeutics, Neurocrine Biosciences, Sumitomo Pharma America, and Teva Pharmaceuticals. Dr. Meyer is an advisor/consultant for Alkermes, Axsome Therapeutics, BioXcel Therapeutics, Cerevel Therapeutics, Intra-Cellular Therapies Inc., Karuna Therapeutics, Neurocrine Biosciences, Otsuka, Relmada Therapeutics, Sumitomo Pharma America, and Teva Pharmaceuticals.

Session Length:  1 hour 30 minutes

Target Audience:  APRN

Learning Outcome:
Upon completion of this presentation, the participant will be able to:

• Discuss emerging evidence-based treatments for schizophrenia

Course Outcome:

• 65% of learners will report an intent to make changes to their practice as a result of completing this course. 

Keywords:  Schizophrenia, Neurobiology, Antipsychotics

Nursing Continuing Professional Development:
1.5 pharmacology contact hours.  * In order to receive contact hours, you must: Listen to presentation, complete an evaluation, and earn a passing score on the post-test before the expiration date. You will have 5 tries to correctly answer the questions on the post-test and a score of 80% is required to pass. Once you have passed and completed an evaluation, the certificate will be generated online, available for you to print immediately. You cannot earn credit unless all steps are completed.

The American Psychiatric Nurses Association is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s Commission on Accreditation.

Release date: July 8, 2024
Access to this course will end: July 31, 2026

© 2024 APNA. Reproducing and distributing this material without the written permission of the American Psychiatric Nurses Association (APNA) is prohibited. 

*For an uninterrupted learning experience, please download and use Google Chrome, Mozilla Firefox, Microsoft Edge, Safari, etc. If you continue to experience issues, you may need to update your browser.